Clinical Trial

A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs

Study acronym: PELICAN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open label, single arm, phase II multicentre study designed to evaluate the efficacy and safety of pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy in patients with HG-NETs who are chemotherapy-naïve for their metastatic disease. The study will be conducted in up to 10 sites and will recruit up to a maximum of 20 evaluable participants.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-29; most recent amendment 2026-01-13.
Status change: Recruiting → Active, Not Recruiting 2026-01-13
Status change: Not Yet Recruiting → Recruiting 2024-09-18
Trial Details
NCT Number NCT06232564
Lead Sponsor Imperial College London
Conditions Neuroendocrine Tumors
Enrollment 20 participants
Start Date 2024-07-08
Primary Completion 2027-10-15 (estimated)
Study Completion 2027-10-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-14